Mapping of the minimal domain encoding a conformational epitope by λ phage surface display:: factor VIII inhibitor antibodies from haemophilia A patients

被引:24
作者
Kuwabara, I
Maruyama, H
Kamisue, S
Shima, M
Yoshioka, A
Maruyama, IN
机构
[1] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA
[2] Nara Med Univ, Dept Pediat, Kashihara, Nara 634, Japan
关键词
bacteriophage lambda; surface expression; fusion protein; affinity selection;
D O I
10.1016/S0022-1759(99)00012-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Haemophilia A patients who receive repeated transfusion of fVIII concentrates often develop inhibitor alloantibodies, resulting in reduced efficacy of the therapy. Determination of fVIII epitopes for the alloantibodies is essential for an understanding of their inhibitory effect on blood coagulation. Random fragments of fVIII displayed on lambda phage particles were selected using two patient plasmas immobilized onto the surface of a microtiter plate. A set of clones defined the minimal domain that consisted of 157 amino acid residues including cysteine at both boundaries. The minimal domain absorbed most of the binding activities of the plasmas to fVIII, suggesting that the domain contains a major determinant for the plasmas. Site-directed mutagenesis and chemical denaturation of the domain confirmed that a tertiary structure formed by the disulfide bridge was recognized by the antibodies. The epitope domain defined overlaps with fVIII binding sites to vWf and phospholipid, and may play an important role in blood coagulation. Thus, the bacteriophage lambda surface display may be useful for mapping the minimal folding domain of various protein antigens that contain a conformational epitope. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:89 / 99
页数:11
相关论文
共 58 条
[1]   3-DIMENSIONAL STRUCTURE OF AN ANTIGEN-ANTIBODY COMPLEX AT 2.8-A RESOLUTION [J].
AMIT, AG ;
MARIUZZA, RA ;
PHILLIPS, SEV ;
POLJAK, RJ .
SCIENCE, 1986, 233 (4765) :747-753
[2]   MOLECULAR-BASIS OF FACTOR-VIII INHIBITION BY HUMAN-ANTIBODIES - ANTIBODIES THAT BIND TO THE FACTOR-VIII LIGHT CHAIN PREVENT THE INTERACTION OF FACTOR-VIII WITH PHOSPHOLIPID [J].
ARAI, M ;
SCANDELLA, D ;
HOYER, LW .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (06) :1978-1984
[3]  
Ausubel F. M., 1994, CURRENT PROTOCOLS MO
[4]  
CADWELL RC, 1994, PCR METH APPL, V3, pS136
[5]   The canine factor VIII cDNA and 5′ flanking sequence [J].
Cameron, C ;
Notley, C ;
Hoyle, S ;
McGlynn, L ;
Hough, C ;
Kamisue, S ;
Giles, A ;
Lillicrap, D .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (02) :317-322
[6]  
Cortese Riccardo, 1995, Current Opinion in Biotechnology, V6, P73, DOI 10.1016/0958-1669(95)80012-3
[7]   Interactions of protein antigens with antibodies [J].
Davies, DR ;
Cohen, GH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :7-12
[8]   MUTATIONS THAT ALLOW DISULFIDE BOND FORMATION IN THE CYTOPLASM OF ESCHERICHIA-COLI [J].
DERMAN, AI ;
PRINZ, WA ;
BELIN, D ;
BECKWITH, J .
SCIENCE, 1993, 262 (5140) :1744-1747
[9]   ASSEMBLY OF FUNCTIONAL BACTERIOPHAGE-LAMBDA VIRIONS INCORPORATING C-TERMINAL PEPTIDE OR PROTEIN FUSIONS WITH THE MAJOR TAIL PROTEIN [J].
DUNN, IS .
JOURNAL OF MOLECULAR BIOLOGY, 1995, 248 (03) :497-506
[10]   INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].
EHRENFORTH, S ;
KREUZ, W ;
SCHARRER, I ;
LINDE, R ;
FUNK, M ;
GUNGOR, T ;
KRACKHARDT, B ;
KORNHUBER, B .
LANCET, 1992, 339 (8793) :594-598